| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.32 | 2e-10 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | 0.23 | 1e-06 |
| mRNA | RAF265 | CCLE | pan-cancer | AAC | 0.21 | 3e-05 |
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | 0.18 | 5e-05 |
| mRNA | PD-0325901 | CCLE | pan-cancer | AAC | 0.17 | 6e-05 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.13 | 0.004 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.13 | 0.007 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.093 | 0.05 |
| mRNA | Panobinostat | CCLE | pan-cancer | AAC | 0.075 | 0.08 |